1. Cytidine Deaminase APOBEC3A Regulates PD-L1 Expression in Cancer Cells in a JNK/c-JUN-Dependent Manner
- Author
-
Meredith A. Morgan, Qiang Zhang, Kailiang Zhao, Weiping Zou, Leslie A. Parsels, Theodore S. Lawrence, Long Jiang, Michael D. Green, Rémi Buisson, Xueting Lang, Joshua D. Parsels, and Sheryl A. Flanagan
- Subjects
Cancer Research ,Proto-Oncogene Proteins c-jun ,DNA damage ,Oncology and Carcinogenesis ,Cell ,Apoptosis ,Article ,B7-H1 Antigen ,Immune system ,Clinical Research ,Interferon ,Neoplasms ,Cytidine Deaminase ,Biomarkers, Tumor ,Tumor Cells, Cultured ,Genetics ,medicine ,Humans ,2.1 Biological and endogenous factors ,Mitogen-Activated Protein Kinase 8 ,Oncology & Carcinogenesis ,Aetiology ,APOBEC3A ,Molecular Biology ,Cell Proliferation ,Cancer ,Neoplastic ,Cultured ,Tumor ,Chemistry ,Proteins ,Cytidine deaminase ,Prognosis ,Immune checkpoint ,Tumor Cells ,Gene Expression Regulation, Neoplastic ,medicine.anatomical_structure ,Gene Expression Regulation ,Oncology ,Cancer cell ,Cancer research ,Biomarkers ,Biotechnology ,Developmental Biology ,medicine.drug - Abstract
Programmed death-ligand 1 (PD-L1) promotes tumor immune evasion by engaging the PD-1 receptor and inhibiting T-cell activity. While the regulation of PD-L1 expression is not fully understood, its expression is associated with tumor mutational burden and response to immune checkpoint therapy. Here, we report that Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3A (APOBEC3A) is an important regulator of PD-L1 expression. Using an APOBEC3A inducible expression system as well as siRNA against endogenous APOBEC3A, we found that APOBEC3A regulates PD-L1 mRNA and protein levels as well as PD-L1 cell surface expression in cancer. Mechanistically, APOBEC3A-induced PD-L1 expression was dependent on APOBEC3A catalytic activity as catalytically dead APOBEC3A mutant (E72A) failed to induce PD-L1 expression. Furthermore, APOBEC3A-induced PD-L1 expression was dependent on replication-associated DNA damage and JNK/c-JUN signaling but not interferon signaling. In addition, we confirmed the relevance of these finding in patient tumors as APOBEC3A expression and mutational signature correlated with PD-L1 expression in multiple patient cancer types. These data provide a novel link between APOBEC3A, its DNA mutagenic activity and PD-L1-mediated antitumoral immunity. This work nominates APOBEC3A as a mechanism of immune evasion and a potential biomarker for the therapeutic efficacy of immune checkpoint blockade. Implications: APOBEC3A catalytic activity induces replication-associated DNA damage to promote PD-L1 expression implying that APOBEC3A-driven mutagenesis represents both a mechanism of tumor immune evasion and a therapeutically targetable vulnerability in cancer cells.
- Published
- 2021
- Full Text
- View/download PDF